论文部分内容阅读
目的探讨不同剂量阿卡波糖联合人预混胰岛素(30/70,重和林M30)治疗T2DM的临床疗效。方法 T2DM患者180例随机分为重和林M30(A)组、重和林M30联合阿卡波糖150mg/d(B)组及重和林M30联合阿卡波糖300mg/d(C)组,疗程12周。结果 12周时3组2hPG和HbA1c,B组和C组FPG、胰岛素日使用剂量及C组体重均降低(P<0.01),且C组上述指标低于A、B组(P<0.05);C组低血糖发生率16.9%,低于A组(46.4%),血糖达标率69.5%,高于A、B组(39.3%、45.6%)(P<0.0167)。结论阿卡波糖300mg/d(100mg,3次/d)在单独应用人预混胰岛素(30/70)出现餐前低血糖和餐后高血糖、餐中碳水化合物摄入量偏高的T2DM患者中适用,其疗效优于阿卡波糖150mg/d(50mg,3次/d)。
Objective To investigate the clinical effects of acarbose plus premixed insulin (30/70, Chonghelin M30) in the treatment of T2DM. Methods One hundred and eighty patients with T2DM were randomly divided into two groups: Chonghelin M30 (A), Chonghelin M30 combined with acarbose 150mg / d (B) and Chonghelin M30 combined with acarbose 300mg / d (C) , Treatment for 12 weeks. Results At 12 weeks, the FPG and daily doses of insulin and the body weight of group C were lower in 2hPG and HbA1c, B and C groups (P <0.01), and the above indexes in C group were lower than those in A and B groups (P <0.05). The incidence of hypoglycemia in group C was 16.9%, lower than that in group A (46.4%), and the rate of blood sugar reaching the standard was 69.5%, higher than that in group A and B (39.3%, 45.6%) (P <0.0167). Conclusion Acarbose 300mg / d (100mg, 3 times / d) appeared to have pre-meal hypoglycemia and postprandial hyperglycemia when using human premixed insulin (30/70) alone, with high intake of carbohydrate in the meal For patients, its efficacy is superior to acarbose 150mg / d (50mg, 3 times / d).